Fluselenamyl in conjuction with positron emission tomography (PET) scans shown effective in diagnosing early Alzheimer’s disease pathology

Researchers at Washington University School of Medicine in St. Louis have developed a chemical compound, named Fluselenamyl, that detects amyloid clumps better than current FDA-approved compounds. If a radioactive atom is incorporated into the compound, its location in a living brain can be monitored using positron emission tomography (PET) scans. The compound, described in a paper …

Fluselenamyl in conjuction with positron emission tomography (PET) scans shown effective in diagnosing early Alzheimer’s disease pathology Read More »